ARVN Q3 2019 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$856M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+790.3% YoY

Gross Profit

$30M100.0% margin

Operating Income

$6M18.3% margin

Net Income

-$18M-58.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+648.2%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$665,603

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$209M

Total Liabilities

$75M

Stockholders' Equity

$134M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$3M	+790.3%
Gross Profit	$30M	$3M	+790.3%
Operating Income	$6M	-$14M	+139.2%
Net Income	-$18M	-$13M	-32.0%